,64 In addition, previous studies have indicated that PI3K/mTOR inhibitors can synergise with PD‐1 blockade in syngeneic mouse models of melanoma, prostate, colorectal and breast cancer.65 This evidence concerns the gene PDCD1 and breast carcinoma.